Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPN14770 PET Study in Healthy Subjects
NCT04044781Phase 1Withdrawn
- Sponsor
- Tetra Therapeutics
- Start
- Jan 2020
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zatolmilast in Fragile X syndrome (FXS) and Alzheimer's disease (AD), sponsored by Tetra Therapeutics. Primary endpoints: Adverse Events, Plasma Concentration at 24 Hours and 1 more. Planned start Jan 2020; status: withdrawn.
02
Drugs
zatolmilast
03
Conditions
Fragile X syndrome (FXS)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04044781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04044781.